OpenLB
Open Library of Bioscience
Advanced Search
Frontiers in cellular neuroscience
2019;13 585.

Treatment With Liraglutide Exerts Neuroprotection After Hypoxic-Ischemic Brain Injury in Neonatal Rats the PI3K/AKT/GSK3β Pathway.

Shan-Shan Zeng, Jun-Jie Bai, Huai Jiang, Jin-Jin Zhu, Chang-Chang Fu, Min-Zhi He, Jiang-Hu Zhu, Shang-Qin Chen, Pei-Jun Li, Xiao-Qin Fu, Zhen-Lang Lin
Author Information
  1. Shan-Shan Zeng: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  2. Jun-Jie Bai: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  3. Huai Jiang: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  4. Jin-Jin Zhu: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  5. Chang-Chang Fu: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  6. Min-Zhi He: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  7. Jiang-Hu Zhu: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  8. Shang-Qin Chen: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  9. Pei-Jun Li: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  10. Xiao-Qin Fu: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
  11. Zhen-Lang Lin: Department of Neonatology, The Second Affiliated Hospital and Yuying Children's Hospital, Wenzhou Medical University, Wenzhou, China.
PMID: 32082121 DOI: 10.3389/fncel.2019.00585

Abstract

Neonatal hypoxic-ischemic (HI) brain injury is a detrimental disease, which results in high mortality and long-term neurological deficits. Nevertheless, the treatment options for this disease are limited. Thus, the aim of the present study was to assess the role of liraglutide in neonatal HI brain injury in rats and investigate the associated mechanisms. The results showed that treatment with liraglutide significantly reduced infarct volume and ameliorated cerebral edema, decreased inflammatory response, promoted the recovery of tissue structure, and improved prognosis following HI brain injury. Moreover, treatment with liraglutide inhibited apoptosis and promoted neuronal survival both in the rat model and following oxygen-glucose deprivation (OGD) insult. LY294002, an inhibitor of phosphoinositide 3-kinase (PI3K), partially reversed these therapeutic effects, suggesting that the PI3K/protein kinase B (Akt) pathway was involved. In conclusion, our data revealed that treatment with liraglutide exerts neuroprotection after neonatal HI brain injury the PI3K/Akt/glycogen synthase kinase-3β (GSK3β) pathway and may be a promising therapy for this disease.

Keywords

PI3K/AKT/GSK3β apoptosis liraglutide neonatal hypoxic-ischemic brain injury neuroprotection

References

  1. Nat Rev Neurol. 2015 Apr;11(4):192-208 [PMID: 25686754]
  2. Neurosci Lett. 2017 Feb 22;641:1-7 [PMID: 28122257]
  3. Mol Cells. 2018 Mar 31;41(3):234-243 [PMID: 29463067]
  4. Neural Regen Res. 2017 Oct;12(10):1625-1631 [PMID: 29171427]
  5. Brain Behav Immun. 2017 Oct;65:125-139 [PMID: 28457811]
  6. Neuropharmacology. 2014 Nov;86:241-58 [PMID: 25107586]
  7. JAMA Pediatr. 2015 Apr;169(4):397-403 [PMID: 25685948]
  8. Ann Neurol. 2011 May;69(5):743-58 [PMID: 21520238]
  9. Acta Pharmacol Sin. 2013 Sep;34(9):1121-30 [PMID: 23892271]
  10. BMC Neurosci. 2012 Mar 23;13:33 [PMID: 22443187]
  11. Curr Diab Rep. 2018 Aug 31;18(10):92 [PMID: 30171481]
  12. J Neurochem. 2011 Mar;116(6):1148-59 [PMID: 21210815]
  13. Theranostics. 2016 Sep 2;6(12):2015-2027 [PMID: 27698937]
  14. Neurochem Res. 2018 Jun;43(6):1210-1226 [PMID: 29696512]
  15. Ann Clin Transl Neurol. 2014 Sep;1(9):721-32 [PMID: 25493285]
  16. N Engl J Med. 2009 Oct 1;361(14):1349-58 [PMID: 19797281]
  17. Exp Neurol. 2019 Jul;317:34-50 [PMID: 30802446]
  18. Sci Rep. 2016 Mar 30;6:23817 [PMID: 27026509]
  19. Drugs Today (Barc). 2009 Feb;45(2):101-13 [PMID: 19343230]
  20. PLoS One. 2015 Mar 30;10(3):e0120074 [PMID: 25822252]
  21. Sci Rep. 2016 May 31;6:26859 [PMID: 27240461]
  22. Cell Death Differ. 2005 Feb;12(2):162-76 [PMID: 15592434]
  23. Mol Metab. 2015 Aug 05;4(10):718-31 [PMID: 26500843]
  24. Cell Rep. 2018 May 15;23(7):1922-1931.e4 [PMID: 29768193]
  25. Diabetol Metab Syndr. 2017 Jan 7;9:3 [PMID: 28074109]
  26. Oncotarget. 2017 Sep 8;8(49):85949-85968 [PMID: 29156769]
  27. Epilepsy Res. 2018 May;142:45-52 [PMID: 29549796]
  28. Int Immunopharmacol. 2018 Dec;65:64-75 [PMID: 30290368]
  29. J Psychopharmacol. 2018 May;32(5):578-590 [PMID: 29493378]
  30. Inflammopharmacology. 2017 Jun;25(3):369-382 [PMID: 28258522]
  31. Prog Neurobiol. 2013 Jul-Aug;106-107:1-16 [PMID: 23583307]
  32. Dev Neurosci. 2005 Mar-Aug;27(2-4):81-6 [PMID: 16046840]
  33. Drugs. 2014 Dec;74(18):2161-74 [PMID: 25367717]
  34. Free Radic Biol Med. 2019 May 1;135:144-156 [PMID: 30862541]
  35. Brain Res. 2001 Nov 16;919(1):106-14 [PMID: 11689167]
  36. Pediatr Neonatol. 2017 Dec;58(6):475-483 [PMID: 28416250]
  37. Neuroreport. 2009 Aug 26;20(13):1161-6 [PMID: 19617854]
  38. J Cell Physiol. 2019 Apr;234(4):5304-5318 [PMID: 30216439]
  39. Free Radic Biol Med. 2019 Oct;142:113-122 [PMID: 31039399]
  40. J Biol Chem. 2013 May 31;288(22):15988-6003 [PMID: 23585565]
  41. Neurobiol Dis. 2016 Jul;91:37-46 [PMID: 26921472]
  42. Cell Mol Neurobiol. 2019 Oct;39(7):953-961 [PMID: 31147852]
  43. J Parkinsons Dis. 2014;4(3):337-44 [PMID: 24662192]
  44. Mol Med Rep. 2018 Aug;18(2):2449-2457 [PMID: 29916537]
  45. Brain Res. 2014 Nov 17;1589:68-77 [PMID: 25304361]
  46. J Cereb Blood Flow Metab. 2014 Jun;34(6):921-32 [PMID: 24667913]
  47. J Neurosci. 2011 Apr 27;31(17):6587-94 [PMID: 21525299]
  48. Pediatr Neurol. 2009 Dec;41(6):399-405 [PMID: 19931160]
  49. J Neurochem. 2015 Dec;135(6):1203-1217 [PMID: 25982185]
  50. Brain Res Brain Res Rev. 2005 Dec 15;50(2):244-57 [PMID: 16216332]
  51. Neural Plast. 2016;2016:4901014 [PMID: 27047695]
  52. Sci Rep. 2017 Dec 13;7(1):17490 [PMID: 29235507]
  53. Postgrad Med. 2018 Mar;130(2):154-158 [PMID: 29350569]
Journal Article
Article has an altmetric score of 1

Word Cloud

Created with Highcharts 10.0.0braininjuryliraglutideHItreatmentdiseaseneonatalNeonatalhypoxic-ischemicresultspromotedfollowingapoptosispathwayneuroprotectionPI3K/AKT/GSK3βdetrimentalhighmortalitylong-termneurologicaldeficitsNeverthelessoptionslimitedThusaimpresentstudyassessroleratsinvestigateassociatedmechanismsshowedsignificantlyreducedinfarctvolumeamelioratedcerebraledemadecreasedinflammatoryresponserecoverytissuestructureimprovedprognosisMoreoverinhibitedneuronalsurvivalratmodeloxygen-glucosedeprivationOGDinsultLY294002inhibitorphosphoinositide3-kinasePI3KpartiallyreversedtherapeuticeffectssuggestingPI3K/proteinkinaseBAktinvolvedconclusiondatarevealedexertsPI3K/Akt/glycogensynthasekinase-3βGSK3βmaypromisingtherapyTreatmentLiraglutideExertsNeuroprotectionHypoxic-IschemicBrainInjuryRatsPathway

Similar Articles

Cited By